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Abstract
Background: Electroacupuncture (EA) can produce analgesia by increasing the b-endorphin level and activation of
peripheral μ-opioid receptors in inflamed tissues. Endogenous cannabinoids and peripheral cannabinoid CB2 receptors
(CB2Rs) are also involved in the antinociceptive effect of EA on inflammatory pain. However, little is known about how
peripheral CB2Rs interact with the endogenous opioid system at the inflammatory site and how this interaction
contributes to the antinociceptive effect of EA on inflammatory pain. In this study, we determined the role of peripheral
CB2Rs in the effects of EA on the expression of b-endorphin in inflamed skin tissues and inflammatory pain.
Results: Inflammatory pain was induced by injection of complete Freund’s adjuvant into the left hindpaw of rats.
Thermal hyperalgesia was tested with a radiant heat stimulus, and mechanical allodynia was quantified using von
Frey filaments. The mRNA level of POMC and protein level of b-endorphin were quantified by real-time PCR and
Western blotting, respectively. The b-endorphin-containing keratinocytes and immune cells in the inflamed skin
tissues were detected by double-immunofluorescence labeling. The CB2R agonist AM1241 or EA significantly
reduced thermal hyperalgesia and mechanical allodynia, whereas the selective μ-opioid receptor antagonist b-
funaltrexamine significantly attenuated the antinociceptive effect produced by them. AM1241 or EA significantly
increased the mRNA level of POMC and the protein level of b-endorphin in inflamed skin tissues, and these effects
were significantly attenuated by pretreatment with the CB2R antagonist AM630. AM1241 or EA also significantly
increased the percentage of b-endorphin-immunoreactive keratinocytes, macrophages, and T-lymphocytes in
inflamed skin tissues, and these effects were blocked by AM630.
Conclusions: EA and CB2R stimulation reduce inflammatory pain through activation of μ-opioid receptors. EA
increases endogenous opioid expression in keratinocytes and infiltrating immune cells at the inflammatory site
through CB2R activation.
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Background
Previous studies have shown that electroacupuncture
produces analgesia through increasing the b-endorphin
level and activating peripheral μ-opioid receptors in the
inflamed tissues [1-3]. We have shown that endogenous
cannabinoids and peripheral cannabinoid CB2 receptors
(CB2Rs) are also involved in the antinociceptive effect of
EA on inflammatory pain [4]. Moreover, EA potentiates
the CB2R expression on keratinocytes, infiltrating macro-
phages and T-lymphocytes in inflamed skin tissues [5],
which might synthesize and release endogenous opioid
peptides to reduce inflammatory pain [6-8]. However, lit-
tle is known about how peripheral CB2Rs interact with
the endogenous opioid system at the inflammatory site
and how this interaction contributes to the antinocicep-
tive effect of EA on inflammatory pain.
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any medium, provided the original work is properly cited.Therefore, in this study, we used a rat model of inflam-
matory pain to test the hypothesis that EA reduces
inflammatory pain by increasing the level of b-endorphin
expressed in keratinocytes and infiltrating immune cells
in inflamed tissues and peripheral μ-opioid receptor acti-
vation through peripheral CB2R stimulation. To this end,
we first determined the effects of the CB2R agonist
AM1241 and EA on inflammatory pain and the role of
peripheral μ-opioid receptors in the analgesic effect of
AM1241 and EA. We then determined the role of CB2Rs
in the effects of EA on the mRNA level of POMC and
the protein level of b-endorphin in the inflamed skin tis-
sues and on the percentage of b-endorphin-containing
keratinocytes and infiltrating immune cells. Our findings
provided new evidence that the interaction between per-
ipheral CB2Rs and endogenous opioids contributes
importantly to the analgesic effect of EA on inflammatory
pain.
Results
Peripheral μ-opioid receptors contribute to the analgesic
effects of AM1241 and EA on inflammatory pain
The purpose of the following experiments is to deter-
mine whether peripheral μ-opioid receptors contribute
to the analgesic effect of the CB2R agonist AM1241 or
EA on inflammatory pain. First, we examined the anti-
nociceptive effects of AM1241 (using the AM1241
vehicle group as the control) and EA (using the sham
EA group as the control) on allodynia and hyperalgesia
induced by complete Freund’s adjuvant (CFA) injec-
tion. Then, we determined whether pretreatment with
the μ-opioid receptor antagonist b-funaltrexamine (b-
FNA) attenuates the antinociceptive effect of AM1241
or EA.
The baseline withdrawal thresholds in all the experimen-
tal groups were similar. CFA injection elicited typical
inflammatory responses, including redness, edema, and
hypersensitivities to noxious stimuli in the injected paw.
These symptoms lasted for about 2 weeks as described
before [9]. A large decrease in the thermal withdrawal
latency and mechanical threshold was observed 1 day after
CFA injection (Figure 1A-D). Compared with the vehicle
group, AM1241 treatment (1 mg/kg) from days 2 to 6 sig-
nificantly increased the thermal withdrawal latency and
mechanical threshold in the inflamed hindpaw (Figure 1A,
C). Pretreatment with b-FNA (250 μg/kg) on days 1, 3 and
5 significantly attenuated the antinociceptive effect of
AM1241 (Figure 1A, C).
EA was applied to GB30 and GB34 for 30 min on days 2,
4 and 6 after CFA injection. EA significantly increased the
thermal withdrawal latency and mechanical threshold,
compared with those in the sham EA group (Figure 1B,
D). Furthermore, pretreatment with b-FNA in the same
hindpaw significantly reduced the effect of EA on thermal
hyperalgesia and mechanical allodynia (Figure 1B, D).
CB2Rs contribute to the potentiating effect of EA on the
mRNA level of POMC and protein level of b-endorphin in
inflamed skin tissues
The objective of the following experiments was to deter-
mine (1) the effects of AM1241 (using the AM1241 vehicle
group as the control) and EA (using the sham EA group as
the control) on the POMC mRNA and b-endorphin pro-
tein levels in inflamed tissues; and (2) whether blocking
CB2Rs attenuates the potentiating effects of AM1241 or
EA (using the AM630 vehicle group as the control) on the
POMC mRNA and b-endorphin protein levels in inflamed
tissues.
The endogenous ligand of the opioid peptide b-endor-
phin is derived from the precursor proopiomelanocortin
(POMC). The POMC mRNA was detected in the skin tis-
sues of all groups. CFA injection increased the mRNA level
of POMC in inflamed skin tissues compared with that in
vehicle-injected rats (Figure 2A). AM1241 or EA signifi-
cantly increased the mRNA level of POMC in inflamed
skin tissues compared with that in the vehicle or sham EA
group (Figure 2A, B). Pretreatment with AM630 signifi-
cantly reversed the effects of AM1241 and EA on the
mRNA level of POMC in inflamed tissues (Figure 2A, B).
The specific b-endorphin protein band (3.5 kDa) was
present in the skin tissues samples obtained from all of
the seven groups (Figure 2C). CFA injection increased the
protein level of b-endorphin in the skin tissues compared
with that in the CFA vehicle group (Figure 2D). Com-
pared with the vehicle group, AM1241 treatment signifi-
cantly increased the protein level of b-endorphin in
inflamed tissues (Figure 2D). Also, the protein level of b-
endorphin in inflamed tissues was significantly higher in
the EA group than in the sham EA group (Figure 2E). In
addition, pretreatment with AM630 in the same hindpaw
significantly attenuated the effects of AM1241 and EA on
the protein level of b-endorphin in the inflamed skin tis-
sues (Figure 2D, E).
CB2R activation and EA have no significant effect on the
mRNA and protein levels of μ-opioid receptor-1 in
inflamed skin tissues
To determine whether CB2R stimulation or EA treat-
ment has any effect on the μ-opioid receptor expression
at the inflammatory site, we measured the mRNA and
protein amount of μ-opioid receptor-1 in inflamed tis-
sues. Treatment with either AM1241 or EA had no sig-
nificant effect on the mRNA and protein levels of μ-
opioid receptor-1 in inflamed skin tissues on day 6 after
CFA injection compared with those in the vehicle group
or sham EA group (Figure 3, A-E).
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level of b-endorphin expressed in keratinocytes of
inflamed skin tissues
The epidermal layer of the skin tissues obtained from
CFA-injected rats became much thicker than that in the
vehicle-injected rats (Figure 4A). The b-endorphin
immunoreactivity was present in keratinocytes located in
the uppermost layer of the epidermis, including the stra-
tum granulosum and the stratum spinosum in the vehicle
control group. Intense b-endorphin-immunoreactivity
w a sd e t e c t e dt h r o u g h o u tt h es t r a t u mg r a n u l o s u ma n d
into the stratum spinosum in inflamed skin tissues (Fig-
ure 4A). The percentage of b-endorphin-immunoreactive
keratinocytes was significantly increased in the skin tis-
sues in CFA-injected rats than that in vehicle-injected
rats (P < 0.05, Figure 4B).
Treatment with AM1241 or EA significantly increased
the percentage of keratinocytes labeled with b-endorphin
compared with that in the vehicle group or sham EA
group (P < 0.05, Figure 4B, C). Furthermore, pretreatment
Figure 1 Time course of the effects of b-FNA on the antinociceptive actions of AM1241 and EA on thermal hyperalgesia and mechanical
allodynia in rats. A, Effects of b-FNA on the AM1241 action on thermal withdrawal latency in response to heat stimulus applied to the inflamed
paw. B, Effects of b-FNA on the analgesic effect of EA on thermal withdrawal latency in response to heat stimulus applied to the inflamed paw. C,
Effects of b-FNA on analgesic action of AM1241 on mechanical withdrawal threshold in response to von Frey filaments applied to the inflamed
paw. D, Effects of b-FNA on the analgesic action of EA on mechanical withdrawal threshold in response to von Frey filaments applied to the
inflamed paw. Time 0 represents baseline values before CFA injection. EA (2 Hz) or sham EA was administered every other day for 30 min, and
AM1241 or its vehicle (50 μL) was injected subcutaneously into the dorsal surface of the left hindpaw of rats at the same time of EA, as indicated by
white arrows. b-FNA or its vehicle was injected 24 hours before AM1241, EA or sham EA treatment as indicated by black arrows. Data are presented
as means ± SEM (n = 8 rats in each group). *P < 0.05, compared with the vehicle control group; #P < 0.05, compared with the CFA+vehicle of
AM1241 group; &P < 0.05, compared with the CFA+AM1241 group; †P < 0.05, compared with the CFA+sham EA+vehicle of b-FNA group; $P <
0.05, compared with the CFA+EA+vehicle of b-FNA group (Two-way ANOVA followed by Bonferroni’s test).
Su et al. Molecular Pain 2011, 7:98
http://www.molecularpain.com/content/7/1/98
Page 3 of 14Figure 2 Effects of AM1241, EA, AM1241 plus AM630, and EA plus AM630 on the mRNA level of POMC (A, B) and the protein level of
b-endorphin (C, D, E) in inflamed skin tissues. A, summary data show the relative mRNA level of POMC in the skin tissues obtained from the
vehicle control (CONT), CFA+vehicle of AM1241 (CFA), CFA+AM1241 (AM1241), and CFA+AM1241+AM630 (AM1241+AM630) groups. B, summary
data show the relative mRNA level of POMC in the skin tissues obtained from the CFA+sham EA+vehicle of AM630 (sham EA), CFA+EA+vehicle
of AM630 (EA), and CFA+EA+AM630 (EA+AM630) groups. C, a representative gel image showing the protein level of b-endorphin in the skin
tissues obtained from 7 groups of rats. b-actin was used as a loading control. The protein band at 3.5 kDa corresponds to the b-endorphin
protein. D-E, summary data show the % increase in the b-endorphin protein level by AM1241 and EA with and without AM630. Data are
expressed as means ± SEM (n = 6 rats in each group). * P < 0.05, compared with the vehicle control group; # P < 0.05, compared with the CFA
+vehicle of AM1241 group; & P < 0.05, compared with the CFA+AM1241 group; †P < 0.05, compared with the CFA+sham EA+vehicle of AM630
group; $ P < 0.05, compared with the CFA+EA+vehicle of AM630 group (One-way ANOVA followed by Tukey’s test).
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Page 4 of 14Figure 3 Effects of AM1241, EA, AM1241 plus AM630, and EA plus AM630 on the mRNA (A, B) and the protein (C, D, E) levels of μ-opioid
receptor-1 in inflamed skin tissues. A, summary data show the relative mRNA level of μ-opioid receptor-1 in the skin tissues obtained from the
vehicle control (CONT), CFA+vehicle of AM1241 (CFA), CFA+AM1241 (AM1241) and CFA+AM1241+AM630 (AM1241+AM630) groups. B, summary data
show the relative mRNA level of μ-opioid receptor-1 in the skin tissues obtained from the CFA+sham EA+vehicle of AM630 (sham EA), CFA+EA
+vehicle of AM630 (EA), and CFA+EA+AM630 (EA+AM630) groups. C, a representative gel image showing the protein level of μ-opioid receptor-1 in
the skin tissues obtained from those 7 groups. b-actin was used as a loading control. Both two bands correspond to the μ-opioid receptor-1 protein.
D-E, summary data show the % increase in the μ-opioid receptor-1 protein level by AM1241 and EA with and without AM630. Data are expressed as
means ± SEM (n = 6 rats in each group). * P < 0.05, compared with the vehicle control group; # P < 0.05, compared with the CFA+vehicle of AM1241
group; & P < 0.05, compared with the CFA+AM1241 group; †P < 0.05, compared with the CFA+sham EA+vehicle of AM630 group; $ P < 0.05,
compared with the CFA+EA+vehicle of AM630 group (One-way ANOVA followed by Tukey’s test).
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Page 5 of 14Figure 4 Effects of AM1241, EA, AM1241 plus AM630, and EA plus AM630 on keratinocytes immunorecative to b-endorphin in the skin
tissues. A, representative confocal images showing pan cytokeratin positive-keratinocytes (KC, green, left panels) and b-endorphin-immunoreactive
cells (b-EP, red, middle panels). The right panels are overlay images showing double-labeled b-endorphin and keratinocytes (Merge, yellow, white
arrows). Images include vehicle control (CONT), CFA+vehicle of AM1241 (CFA), CFA+AM1241 (AM1241), CFA+AM1241+AM630 (AM1241+AM630), CFA
+sham EA+vehicle of AM630 (sham EA), CFA+EA+vehicle of AM630 (EA), and CFA+EA+AM630 (EA+AM630) groups (Scale bar, 50 μm). B-C, summary
graphs show the percentage of keratinocytes labeled with b-endorphin (b-EP) in the total of pan cytokeratin-positive cells in the skin tissues. Data are
expressed as means ± SEM (n = 6 rats in each group). * P < 0.05, compared with the vehicle control group; # P < 0.05, compared with the CFA
+vehicle of AM1241 group; & P < 0.05, compared with the CFA+AM1241 group; †P < 0.05, compared with the CFA+sham EA+vehicle of AM630
group; $ P < 0.05, compared with the CFA+EA+vehicle of AM630 group (One-way ANOVA followed by Tukey’st e s t ) .
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Page 6 of 14with AM630 in the same hindpaw significantly attenuated
the effect of AM1241 or EA treatment on the percentage
of keratinocytes immunoreactive to b-endorphin in the
inflamed skin tissues (P < 0.05, Figure 4B, C).
CB2Rs contribute to the potentiating effect of EA on the
level of b-endorphin expressed in macrophages of
inflamed skin tissues
In vehicle-injected rats, only a few ED1-positive macro-
phages were found in the dermis of the skin, and the sizes
of these cells were much smaller than those in the CFA-
treated group. Also, ED1-positive macrophages were rarely
labeled with b-endorphin in the skin tissues of vehicle-
injected rats. In contrast, there were large numbers of
infiltrating macrophages in the inflamed skin of CFA-
injected rats. These cells were generally large in sizes and
multivacuolated, and many of them were immunoreactive
to b-endorphin (Figure 5A). The percentage of macro-
phages labeled with b-endorphin was also significantly
increased in the inflamed skin tissues than that in vehicle-
injected rats (P < 0.05, Figure 5B).
AM1241 or EA treatment significantly increased the
percentage of macrophages labeled with b-endorphin in
the inflamed skin tissues compared with the vehicle group
or sham EA group (P < 0.05, Figure 5B, C). Furthermore,
pretreatment with AM630 in the same hindpaw signifi-
cantly blocked the effects of AM1241 and EA on the per-
centage of macrophages immunoreactive to b-endorphin
in the inflamed skin tissues (P < 0.05, Figure 5B, C).
CB2Rs contribute to the potentiating effect of EA on the
level of b-endorphin expressed in T-lymphocytes of
inflamed skin tissues
TCR-positive T-lymphocytes were present in the dermis
of the skin sections obtained from CFA-injected rats and
had the size and oval shape consistent with the typical
characteristics of T-lymphocytes [10]. However, these
cells were rarely present in the rat skin tissues in the
vehicle-injected rats, and only few of them were immu-
noreactive to b-endorphin. In the skin tissues from CFA-
treated rats, there was a marked increase in infiltrating
TCR-positive T-lymphocytes and some of them were
labeled with b-endorphin (Figure 6A). Also, the percen-
tage of T-lymphocytes labeled with b-endorphin in the
total of T-lymphocytes was significantly increased in the
inflamed skin tissues compared with that in the control
skin tissues (P < 0.05, Figure 6B).
Treatment with AM1241 or EA significantly increased
the percentage of T-lymphocytes immunoreactive to b-
endorphin in the inflamed skin tissues compared with
that in the vehicle group or sham EA group (P < 0.05,
Figure 6B, C). Pretreatment with AM630 in the same
hindpaw significantly reversed the effect of AM1241 or
EA treatment on the percentage of T-lymphocytes
labeled with b-endorphin in the inflamed skin tissues
(P < 0.05, Figure 6B, C).
Discussion
It has been reported that endogenous opioid peptides
released from immune cells can act on opioid receptors
on peripheral sensory nerves to reduce inflammatory
pain [11]. Endogenous opioid peptides have been found
in increased levels in the inflamed tissue with b-endor-
phin being the most abundant [6,7,12]. The μ-opioid
receptors are distributed on the peripheral sensory
nerves and their terminals [13], and the μ-opioid recep-
tor-positive nerve fibers in the subcutaneous tissue are
significantly increased after tissue inflammation [14]. It
has been reported that EA increases the content of b-
endorphin in the inflamed tissues [1]. The analgesic
effect of EA on pain caused by carrageenan injection is
dose-dependently antagonized by intraplantar (i.pl.)
injection, but not by intraperitoneal (i.p.) or intravenous
(i.v.) administration of naloxone or selective μ-opioid
receptor antagonists [2,3]. Although both CB1Rs and
CB2Rs are found in peripheral tissues [15,16], activation
of peripheral CB2Rs produces a particularly potent
analgesic effect on inflammatory pain [17,18]. We have
shown that the antinociceptive effect of EA on inflam-
matory pain is blocked by CB2R, but not CB1R, antago-
nists [4]. Furthermore, EA treatment significantly
potentiates the anandamide concentration in inflamed
skin tissues [4] and increases the number of CB2R-posi-
tive keratinocytes, macrophages, and T-lymphocytes at
the site of tissue inflammation [5]. In the present study,
we found that b-FNA, a selective and irreversible μ-
opioid receptor antagonist [19], reversed the inhibitory
effect of EA or the CB2R agonist AM1241 on thermal
hyperalgesia and mechanical allodynia caused by CFA.
Thus, our results suggested that peripheral μ-opioid
receptors contribute to the analgesic effects of AM1241
and EA in inflammatory pain conditions.
The most salient finding of our present study is that the
CB2R agonist AM1241 and EA significantly increased the
mRNA level of POMC and protein level of b-endorphin in
the inflamed skin tissues. The potentiating effects of
AM1241 and EA on POMC and b-endorphin expression
were largely blocked by local administration of the CB2R
antagonist AM630. Thus, our data suggested that periph-
eral CB2Rs contribute to the potentiating effects of
AM1241 and EA on the expression level of POMC and b-
endorphin at the site of inflammation. POMC-related
opioid peptides have been found in leukocytes of many
vertebrates and invertebrates [20]. POMC transcripts are
upregulated in lymphocytes from rats with paw inflamma-
tion [21], and the enzymes (e.g., prohormone convertases
and carboxypeptidase) required for proteolytic processing
of POMC are expressed in leukocytes [22]. Another type
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Page 7 of 14Figure 5 Effects of AM1241, EA, AM1241 plus AM630, and EA plus AM630 on macrophages labeled with b-endorphin in the skin tissues.
A, representative confocal images showing ED1-positive macrophages (ED, green, left panels) and b-endorphin-immunoreactive cells (b-EP, red,
middle panels). The right panels are overlay images showing double-labeled b-endorphin and macrophages (Merge, yellow, white arrows). Images
include vehicle control (CONT), CFA+vehicle of AM1241 (CFA), CFA+AM1241 (AM1241), CFA+AM1241+AM630 (AM1241+AM630), CFA+sham EA
+vehicle of AM630 (sham EA), CFA+EA+vehicle of AM630 (EA), and CFA+EA+AM630 (EA+AM630) groups (Scale bar, 50 μm). B-C, summary graphs
show the percentage of macrophages labeled with b-endorphin (b-EP) in the total of ED1-positive macrophages in the skin tissues. Data are
expressed as means ± SEM (n = 6 rats in each group). * P < 0.05, compared with the vehicle control group; # P < 0.05, compared with the CFA
+vehicle of AM1241 group; & P < 0.05, compared with the CFA+AM1241 group; †P < 0.05, compared with the CFA+sham EA+vehicle of AM630
group; $ P < 0.05, compared with the CFA+EA+vehicle of AM630 group (One-way ANOVA followed by Tukey’s test).
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Page 8 of 14Figure 6 Effects of AM1241, EA, AM1241 plus AM630, and EA plus AM630 on T-lymphocytes with b-endorphin immunorecativity in the
skin tissues. A, representative confocal images show TCR-positive T-lymphocytes (TC, green, left panels) and b-endorphin-immunoreactive cells (b-
EP, red, middle panels). The right panels are overlay images showing T-lymphocytes labeled with b-endorphin (Merge, yellow, white arrows).
Images include vehicle control (CONT), CFA+vehicle of AM1241 (CFA), CFA+AM1241 (AM1241), CFA+AM1241+AM630 (AM1241+AM630), CFA
+sham EA+vehicle of AM630 (sham EA), CFA+EA+vehicle of AM630 (EA), and CFA+EA+AM630 (EA+AM630) groups (Scale bar, 50 μm). B-C,
summary graphs show the percentage of double-labeled T-lymphocytes labeled with b-endorphin (b-EP) in the total of TCR-positive T-lymphocytes
in the skin tissues. Data are expressed as means ± SEM (n = 6 rats in each group). * P < 0.05, compared with the vehicle control group; # P < 0.05,
compared with the CFA+vehicle of AM1241 group; & P < 0.05, compared with the CFA+AM1241 group; †P < 0.05, compared with the CFA+sham
EA+vehicle of AM630 group; $ P < 0.05, compared with the CFA+EA+vehicle of AM630 group (One-way ANOVA followed by Tukey’s test).
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cytes, which synthesize POMC and its derivatives b-LPH
and b-endorphin [23,24]. It has been reported that
AM1241 stimulates b-endorphin release from the paw
glabrous skin and cultured human keratinocytes (HaCaT)
cells [25]. Naloxone can reverse the antinociceptive effects
produced by local injection of AM1241 [25]. CB2R activa-
tion by AM1241 and EA may stimulate the expression
level and release of b-endorphin, which then acts on per-
ipheral μ-opioid receptors to inhibit nociception [26]. It
remains unclear how CB2R activation leads to increased
POMC and b-endorphin expression level during tissue
inflammation. Activation of CB2Rs promotes the phos-
phorylation of p42/p44 mitogen-activated protein kinase
(MAPK) [27,28], and activa t i o no fp 4 2 / p 4 4M A P Ki s
linked to increased expression of the growth-related gene
Krox-24 [27]. Also, activation of the CB2Rs induce upre-
gulation of nine genes involved in cytokine synthesis, regu-
lation of transcription, and cell differentiation; most of
which are under the control of the transcription factor
NF-B [29]. It is possible that activation of CB2Rs may
modulate the expression of POMC and b-endorphin
through the MAP kinase signaling cascade. Our study pro-
vides novel evidence that CB2R activation by AM1241 and
EA increases the b-endorphin expression level, which con-
tributes to the analgesic effect of EA on inflammatory
pain.
During inflammation, preexisting or newly synthesized
μ-opioid receptors in the primary sensory neurons are
transported to the inflamed tissue and the spinal dorsal
horn [30]. Increased peripheral μ-opioid receptor expres-
sion can last up to 3 days after tissue inflammation
[14,31], and an increase in μ-opioid receptor mRNA level
can occur in the dorsal root ganglia (DRG) 1 to 2 h after
CFA injection [32]. Previous studies showed that there are
no changes in the mRNA and protein levels of μ-opioid
receptors in the DRG or the paw tissues 7 days after CFA-
induced inflammation [33]. In the present study, we found
no evidence that AM1241 or EA altered the mRNA and
protein levels of μ-opioid receptors in the inflamed tissues.
Because EA treatment can increase the level of endogen-
ous anandmide [4,5] and the level of b-endorphin in the
inflamed skin tissues, activation of CB2Rs could amplify
the analgesic effect of EA by increasing the amount of
endogenous opioid ligands but not the μ-opioid receptor
expression level. Our findings highlight the important role
of interactions between peripheral CB2Rs and the endo-
genous opioid system in the antinociceptive effect of EA
on inflammatory pain.
We further identified the cell types involved in increased
b-endorphin level in the inflamed skin tissues by AM1241
and EA treatment. Immune cells (e.g., macrophages and
T-lymphocytes) recruited to the inflammatory site and
keratinocytes can synthesize and release b-endorphin
[6,12,21,34-36]. In the present study, we found CFA-
induced inflammation significantly increased the percen-
tage of keratinocytes, macrophages, and T-lymphocytes
that are immunoreactive to b-endorphin in inflamed
tissues. Interestingly, both AM1241 and EA treatments
produced a further increase in the percentage of keratino-
cytes, macrophages, and T-lymphocytes labeled with
b-endorphin in the inflamed skin tissues. EA treatment
can increase the anadamide level and the percentage of
keratinocytes, macrophages, and T-lymphocytes expres-
sing CB2Rs [4,5]. Also, the antinociceptive actions of EA
are mediated by local CB2Rs [4]. It has been reported that
CB2R activation can increase the release of b-endorphin
from keratinocytes [5]. Because EA increased the percen-
tage of b-endorphin-containing keratinocytes, macro-
phages, and T-lymphocytes in inflamed tissues and the EA
analgesic effect was blocked by a selective μ-opioid recep-
tor antagonist, it is likely that EA increases the release of
b-endorphin from keratinocytes, macrophages, and T-lym-
phocytes at the site of inflammation.
Conclusions
In summary, we found that peripheral μ-opioid receptors
contribute importantly to the antinociceptive effect pro-
duced by CB2R activation and EA in a rat model of inflam-
matory pain. Through activation of CB2Rs, EA significantly
increases the mRNA level of POMC, the protein level of b-
endorphin, and the percentage of keratinocytes, macro-
phages, and T-lymphocytes expressing b-endorphin in the
inflamed skin tissues. Our study provided novel evidence
that EA upregulates the endogenous opioid system by acti-
vating peripheral CB2Rs. This new information improved
our understanding of the mechanisms underlying acupunc-
ture analgesia. The interaction between endogenous opioid
and cannabinoid systems at the inflammatory site could
lead to improved treatments for inflammatory pain
conditions.
Methods
Animal models
Experiments were carried out on male adult Sprague-Daw-
ley rats (180-200 g) purchased from Experimental Animal
Center of Tongji Medical College of Huazhong University
of Science and Technology. All procedures were approved
by the Animal Care Committee at Huazhong University of
Science and Technology and conformed to the ethical
guidelines of the International Association for the Study of
Pain [37]. The rats were individually housed in cages with
a 12-hr light/dark cycle and had free access to food and
water.
Inflammation was induced by injecting 50 μLo fc o m -
plete Freund’s adjuvant (CFA; Sigma, St. Louis, MO) sub-
cutaneously into the dorsal surface of left hindpaw of rats
using a 25-gauge hypodermic needle [38]. The injections
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inhalation. We selected the dorsal surface of the hindpaw
as the injection site in order to produce an inflammatory
pain focus in Gallbladder Channel of Foot Shaoyang,
where GB30 and GB34 are located, according to the mer-
idian theory of traditional Chinese medicine [4,39]. In
separate rats, mineral oil was injected into the dorsal sur-
face of the hindpaw and was used as the vehicle control.
Electroacupuncture (EA) treatment
In the EA treatment group, the rats received EA on the
ipsilateral “Huantiao” (GB30) and “Yanglingquan”
(GB34) once every other day, starting at the second day
after CFA injection. EA (1 mA and 0.1 ms) was adminis-
tered at 2 Hz for 30 min. Current was delivered with a
modified current-constant Han’s Acupoint Nerve Stimu-
lator (LH202, Huawei Co.Ltd., Beijing, China). GB30
and GB34 were chosen based on their effective use in
reducing inflammatory pain in rats [4,9].
Two acupuncture needles were inserted into two acu-
points corresponding to GB30 and GB34 in humans.
GB30 is located at the junction of the lateral 1/3 and
medial 2/3 of the distance between the greater trochanter
and the hiatus of the sacrum; and GB34 lies on the lateral
aspect of the leg in the depression anterior and inferior to
the head of the fibula in rats [40]. During EA treatment,
each rat was placed in an inverted clear plastic chamber
(approximately 4 cm × 4 cm × 11 cm) but was not
restrained. The animals remained still during EA treat-
ment and showed no evident signs of distress. For sham
control, acupuncture needles were inserted ipsilaterally
into GB30 and GB34 without electrical stimulation or
manual needle manipulation.
Drug administration
AM1241 is a potent and selective CB2R agonist [41].
AM630 is a highly specific CB2R antagonist with a
70-165-fold selectivity for the CB2R in vitro [42]. AM1241
(1 mg/kg, Enzo Life Sciences, PA, USA) and AM630
(150 μg/kg, Enzo Life Sciences, PA, USA) were dissolved
in the vehicle solution containing 5% Tween-80 and 5%
DMSO in normal saline. b-FNA is a selective and irrever-
sible μ-opioid receptor antagonist [19]. b-FNA (250 μg/kg,
Sigma, St. Louis, MO, USA) was dissolved in methanol.
The dose of AM1241, AM630 and b-FNA was selected
based on the previous studies [4,41,43] and our prelimin-
ary dose-response study and was the lowest that produced
reproducible behavioral effects. AM1241 or its vehicle
(50 μL) was injected subcutaneously into the dorsal sur-
face of the left hindpaw of rats once every other day, start-
ing at the second day after CFA injection. AM630 or the
vehicle (50 μL) was injected subcutaneously into the dorsal
surface of the left hindpaw at the same injection time of
AM1241 or 5 min before EA or sham EA treatment each
time. b-FNA or the vehicle (50 μL) was injected subcuta-
neously into the dorsal surface of the left hindpaw 24 h
before AM1241, EA or sham EA treatment each time. The
investigators involved in behavioral tests and biochemical
assays were blinded to the drug injection throughout the
study.
Nociceptive behavioral tests
The behavioral tests were performed 3 times before CFA
injection and once every day, starting from the first day
after CFA injection. The animals were habituated to the
testing environment for 30 min. Thermal hyperalgesia was
assessed by exposing the mid-plantar surface of the hind-
paw to a beam of radiant heat through a transparent glass
surface using a plantar analgesia meter (Ugo Basile, Italy),
as previously described [44]. The withdrawal latency was
recorded for both left and right hindpaws as the time
taken from the onset of radiant heat stimulation to with-
drawal of the hindpaw.
Mechanical allodynia was assessed by placing rats on an
elevated mesh floor, and the tactile threshold was mea-
sured by using an electronic von Frey anesthesiometer
(Ugo Basile, Italy) applied to the plantar surface of the left
hindpaw. The force (g) needed to produce a paw withdra-
wal response was tested 4 times separated by 2- to 3-min
intervals. A mean value of 4 consecutive measurements
was used.
Real-time PCR procedures
The skin tissues (5 mm × 5 mm × 2 mm) at the site of
CFA or vehicle injection were removed on day 6 after
CFA injection (i.e., 25 min after the third EA treatment or
60 min after the third AM1241 treatment). The skin tis-
sues were excised from rats immediately after the animals
were anesthetized with an overdose of sodium pentobarbi-
tone (120 mg ⁄kg, i.p.) and decapitated. Total RNA was iso-
lated from the skin specimens using Trizol reagent
(Invitrogen, CA, USA). Aliquots of 3 μg total RNA were
reverse transcribed into cDNA using ReverTra Ace-a-TM
(Toyobo, Osaka, Japan). The 20 μL (total volume) of the
PCR mixture consisted of 1 μL diluted cDNA, 10 μL
SYBR green-PCR master mixture (2×) (Toyobo, Osaka,
Japan), and 0.3 μM of each primer. Real-time PCR was
performed using the Stratagene Mx3005P. Sequence-
specific primers were listed in Table 1.
The expression level of each gene was determined by
the threshold cycle (CT). Samples that had larger
amounts of a particular gene had correspondingly lower
CT values. For each sample, a CT value was obtained for
POMC, μ-opioid receptor-1, and b-actin. The CT value
of b-actin was subtracted from that of POMC or μ-opioid
receptor-1 to obtain a ΔCT value. The mRNA amount,
normalized to the endogenous control (b-actin), was
given by 2
-ΔΔCt. Results of six independent experiments
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of the vehicle control group.
Western blotting
The plantar skin of the left hindpaw (5 mm × 5 mm × 2
mm) was removed as described above, minced with scis-
sors, and homogenized in 300 μL RIPA Lysis Buffer (Beyo-
time Biotechnology, Nanjing, China) with 2 mM
phenylmethylsulfonyl fluoride and the protease inhibitor
cocktail (Roche Applied Science, CT, USA), and centri-
fuged at 12,000 × g for 10 min. The pellet was discarded
and protein concentrations from the supernatant were
determined using the Enhanced BCA Protein Assay Kit
(Beyotime Biotechnology, Nanjing, China). To quantify b-
endorphin protein level, 150 μg total protein of each tissue
was processed with 2 × Tricine-SDS-PAGE loading buffer
(Tiandz Biotech, Beijing, China), and then separated on
SDS-PAGE gel as previously described [45]. To determine
the μ-opioid receptor-1 protein level, 30 μg total protein
of each tissue was processed with 5 × SDS-PAGE loading
buffer at 95°C for 5 min, and then separated on a 12% gly-
cine-SDS-PAGE gel. The proteins were transferred onto a
PVDF membrane, blocked for 1 hr in 5% nonfat dry milk
in Tris-buffered saline (TBS) containing 0.1% Tween-20.
The membrane was incubated with the rabbit anti-b-
endorphin antibody (1:20,000; Abcam, San Francisco, CA,
USA) and rabbit anti-μ-opioid receptor-1 antibody (1:200;
Santa Cruz, CA, USA) at 4°C overnight, respectively. The
molecular weight of the protein band detected matched
with that reported in previous studies. The specificity of
the anti-b-endorphin antibody has been shown by detect-
ing the specific b-endorphin band at 3.5 kDa [22]. Blotting
using the μ-opioid receptor-1 antibody resulted in two
protein bands at ~50 and ~70 kDa [46,47]. After washes
in 0.1% TBS-Tween 20, the membranes were then incu-
bated with a horseradish peroxidase-conjugated goat anti-
rabbit secondary antibody (1:20000; Jackson ImmunoRe-
search, MD, USA) for 1 h at room temperature, and then
washed three times. The enhanced chemiluminescence
method (ECL Plus Western blotting detection reagents;
Pierce, IL, USA) was used to reveal the protein bands
according to the manufacturer’s protocol. The optical den-
sity of each band was then measured with a computer-
assisted imaging analysis system (Quantity one, Bio-Rad,
Hemel Hempstead, UK) and normalized with b-actin.
Results of six independent experiments were expressed as
the % change over the protein amount in the CFA vehicle
control group.
Double-immunofluorescence labeling procedures
Rats were deeply anesthetized with an overdose of sodium
pentobarbitone (120 mg/kg, i.p.) and were transcardially
perfused with normal saline and 4% paraformaldehyde in
0.1 M phosphate buffer at pH 7.4. The skin tissues with
the injection point in the middle was harvested. Tissues
were postfixed at 4°C in the perfusion fixative for 8 h,
cryoprotected in 30% sucrose overnight, and sectioned at
15 μm on a cryostat in a plane perpendicular to the skin
surface and parallel to the long axis of the foot. The sec-
tions were mounted onto gelatin-coated slides, air-dried
overnight, and used for double-immunofluorescence label-
ing of b-endorphin with markers of keratinocytes, macro-
phages, or T-lymphocytes [14,25].
Double immunolabeling was performed with rabbit anti-
b-endorphin (1:500; Abcam, Cambridge, UK) and mouse
monoclonal anti-pan cytokeratin antibody (1:100; Abcam,
Cambridge, UK) for identification of keratinocytes, mouse
monoclonal anti-CD68 antibody (Clone ED1, 1:200; Sero-
tec, Oxford, UK) for detection of macrophages, or mouse
monoclonal anti-ab T cell receptor (TCR) antibody
(Clone R73, 1:200; BD Biosciences-PharMingen, San
Diego, CA, USA) for identification of T-lymphocytes. The
specificity of the b-endorphin antibody has been demon-
strated by antigen preabsorption with the corresponding
blocking peptides. The anti-pan cytokeratin antibody
reacts specifically with the skin epidermal keratinocytes
[48]. The anti-CD68 antibody specifically labels macro-
phages in the tissues [49]. The anti-TCR antibody is a spe-
cific marker for peripheral T-lymphocytes and does not
react with gδ TCR-bearing T cells [50].
All sections were blocked for 30 min with 5% donkey
serum and 0.2% Tween-20 in PBS, followed by incubation
a t3 7 ° Cf o r1h rt h e na t4 ° Co v e r n i g h tw i t ht h ep r i m a r y
antibody diluted in PBS containing 5% bovine serum albu-
min (BSA). The sections were washed 4 times with 0.05%
Tween-20 in PBS for 5 min, and incubated with a mixture
of secondary antibodies: donkey anti-mouse IgG conju-
gated with Dynight 488 (1:400; Jackson ImmunoResearch)
and donkey anti-rabbit IgG conjugated with Dynight 594
(1:500; Jackson ImmunoResearch). Sections were washed
4 times with 0.05% Tween-20 in PBS for 5 min, and then
treated with the fluorescence-mounting medium to inhibit
quenching of fluorescence before being coverslipped.
Negative controls were included by omitting the primary
antibodies and with primary antibodies preabsorbed with
their specific blocking peptides in the above procedures,
which resulted in no positive labeling in the skin tissues.
Table 1 List of primers used for real-time PCR
Gene names primers
POMC sense, 5’- GCAACGGAGATGAACAGCC-3’
antisense, 5’- TCTTCCTCCGCACGCCTCT-3’
μ-opioid receptor-1 sense, 5’-GCATTGCTTTGGGTTACACG-3’
antisense, 5’-CTGTATTAGCCGTGGAGGGA-3’
b-actin sense, 5’-CACCCGCGAGTACAACCTTC-3’
antisense, 5’-CCCATACCCACCATCACACC-3’
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ing and cell counting.
Imaging acquisition and analysis
Digital confocal images were acquired using a laser scan-
ning confocal microscope (FV500-IX71, Olympus, Japan).
The sections were scanned using excitation at 488 nm
(argon laser) for Dylight 488 and at 594 nm (helium neon
laser) for Dylight 594. A total of 3-4 sections were imaged
from the same skin tissues in each rat, and counting of
single- and double-labeled cells was done on confocal
images randomly taken from three view fields in each sec-
tion. Cell counting was performed by an investigator in a
blind fashion using NIH Image J software (Bethesda, MD,
USA). The percentage of double-labeled cells in the total
of single-labeled cells was used for statistical analysis.
Statistical analysis
Data are presented as means ± SEM. We used one-way
ANOVA (mRNA and protein levels and the percentage
of double-labeled cells) or two-way ANOVA (behavioral
data) to determine the overall effect of interventions.
Tukey’s post hoc test was then used to determine the sta-
tistical difference in the mRNA and protein levels and the
percentage of double-labeled cells between individual
groups. To determine the statistical difference in the
withdrawal thresholds between different groups and time
points, we used Bonferroni’s post hoc test. A P value of
less than 0.05 was considered statistically significant.
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